PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100200700032C — MODIFICATION 12

MODIFICATION 12 is a federal NONE award for Department of Health and Human Services (HHS) held by BIOCRYST PHARMACEUTICALS, INC.. Estimated value $205.3M ($-29.9M obligated). Current period of performance ends Apr 30, 2014. Last award drew 7 bidders. Place of performance: BIRMINGHAM, AL. Related solicitation DHSORDCVB0601.

$205.3M
Estimated Value
$-29.9M
Obligated
Apr 30, 2014
PoP End / Expires
7
Bidders (last award)
More in SCOUT — score this to your firm →See related expiring contracts →

Analysis

Public

BIOCRYST PHARMACEUTICALS, INC. holds $-26,665,936 across 20 federal awards. Competition previously drew 7 offers. Set-aside status: NONE. PoP ended Apr 30, 2014 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Contract facts

NONE
Contract numberHHSO100200700032C
AgencyDepartment of Health and Human Services (HHS)
IncumbentBIOCRYST PHARMACEUTICALS, INC.
UEIMGXADJ6SCLJ5
NAICS541710

No full NAICS 541710 intel page yet. Browse NAICS intelligence

PSCAN13
Place of performanceBIRMINGHAM, AL
Related solicitationDHSORDCVB0601
PoP end (current)Apr 30, 2014
Obligated$-29.9M

Recompete timing

Public
Past PoP end (4485 days ago)

Current PoP ended Apr 30, 2014 (4485 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Track recompete timing in SCOUT →

Incumbent footprint

Public record

BIOCRYST PHARMACEUTICALS, INC.$-26,665,936 obligated across 20 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)
Department of Veterans Affairs (VA)$1.6M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Score this to your firm — $90 Pilot →

Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. 90 days · $90 · no annual contract · cancel anytime

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open BIOCRYST PHARMACEUTICALS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract HHSO100200700032C?

HHSO100200700032C (MODIFICATION 12) is a Department of Health and Human Services (HHS) award with an estimated value of $205.3M, currently held by BIOCRYST PHARMACEUTICALS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on HHSO100200700032C?

BIOCRYST PHARMACEUTICALS, INC. is the incumbent with $-26,665,936 across 20 related awards in SCOUT’s public footprint. The current period of performance ends Apr 30, 2014.

When does HHSO100200700032C come up for recompete?

SCOUT tracks a period-of-performance end of Apr 30, 2014. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSO100200700032C